Search
OKYO Pharma Ltd
OKYOAdd to Watchlist
1.560USD
+0.040+2.63%
Close 08-17 16:00（ET）Quotes delayed by 15 min
79.77MMarket Cap
LossP/E TTM
More Details of OKYO Pharma Ltd Company
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
OKYO Pharma Ltd Profile
Ticker SymbolOKYO
Company nameOKYO Pharma Ltd
IPO dateJul 17, 2018
CEOJacob (Gary S)
Number of employees4
Security typeOrdinary Share
Fiscal year-endJul 17
AddressFloor 4, 14/15 Conduit St
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeW1S 2XJ
Phone442074952379
Websitehttps://okyopharma.com/
Ticker SymbolOKYO
IPO dateJul 17, 2018
CEOJacob (Gary S)
Company Executives of OKYO Pharma Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Senior Non-Executive Director
Senior Non-Executive Director
--
-100.00%
Mr. Bernard F. Denoyer, CPA
Mr. Bernard F. Denoyer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
FAQs
Who are the top five shareholders of OKYO Pharma Ltd?
The top five shareholders of OKYO Pharma Ltd are: Dr. Raj Patil
How many institutions hold shares of OKYO Pharma Ltd (OKYO)?
As of 2026Q1, 19 institutions hold shares of OKYO Pharma Ltd, with a combined market value of approximately 4.78M, accounting for 9.11% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1185385.00.